Intended for healthcare professionals

Letters Histology independent cancer drugs

Histology independent cancer drugs: the drug makers’ responsibility

BMJ 2020; 368 doi: (Published 03 February 2020) Cite this as: BMJ 2020;368:m350
  1. Daniel A Ollendorf, associate professor
  1. Tufts University Medical Center, Boston, MA 02111, USA
  1. dollendorf{at}

Cooper and colleagues raise important challenges for health technology assessment (HTA) organisations in evaluating the benefits, risks, and cost effectiveness of drugs that target a genetic mutation independent of tumour type.1 Asking manufacturers for more robust …

View Full Text

Log in

Log in through your institution


* For online subscription